Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Benzinga Newsdesk www.benzinga.com Negative 91.7%

Neg 91.7% Neu 0% Pos 0%

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.